Can I Take Melatonin With My Other Medications?

How does melatonin interact with other medications?

Melatonin is a hormone your pineal gland releases in the evening to signal sleep. When you take a supplement, the liver breaks it down quickly using an enzyme called CYP1A2 1Ref 1Facciolà G, Hidestrand M, von Bahr C, Tybring G (2001).Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes.CYP1A2 is the dominant enzyme mediating melatonin metabolism; basis for drug interactions involving CYP1A2 inhibitors or inducers. Any drug that slows CYP1A2 will cause melatonin to build up well above the level you intended; any drug that speeds it up will clear melatonin faster, potentially reducing its effect.

Beyond that enzyme pathway, melatonin has two pharmacological effects of its own that can add to, or partially offset, other medications: mild sedation and a modest blood-pressure-lowering action 2Ref 2Tuft C, Matar E, Menczel Schrire Z, Grunstein RR, Yee BJ, Hoyos CM (2023).Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults.Peak melatonin concentrations in older adults up to 240% higher than younger adults; fall risk, blood pressure effects with nifedipine, interaction magnitude with fluvoxamine (2.8- to 12-fold increase), warfarin case evidence, and sedation risk. Together, these three mechanisms — enzyme competition, additive sedation, and blood pressure effects — explain nearly every clinically meaningful interaction.

Which medications interact with melatonin most significantly?

Antidepressants, especially fluvoxamine. Fluvoxamine (brand: Luvox), an SSRI used for OCD and depression, is by far the most potent inhibitor of CYP1A2 among all common antidepressants [3, 4]. A clinical study in healthy volunteers found that fluvoxamine increased melatonin blood levels by a factor of 2.8 to 12-fold over placebo 3Ref 3von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S (2000).Fluvoxamine but not citalopram increases serum melatonin in healthy subjects — an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.Fluvoxamine increased 20-hour melatonin AUC by a factor of 2.8 vs. placebo in a randomized double-blind crossover study; citalopram had no effect, demonstrating the CYP1A2 specificity of this interaction. In practice, a person on fluvoxamine who takes a standard 5 mg melatonin tablet may be receiving the equivalent of 15–60 mg of circulating melatonin — far more sedation than expected. Other SSRIs (fluoxetine, paroxetine, citalopram) have minimal or no clinically significant effect on CYP1A2 4Ref 4Härtter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, Hiemke C (2001).Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.Fluvoxamine is a potent inhibitor of melatonin degradation (Ki 0.02 µM via CYP1A2); fluoxetine, paroxetine, citalopram, imipramine, and desipramine show minimal effects at therapeutic concentrations. If you are on fluvoxamine, starting with the lowest possible melatonin dose and informing your prescriber is essential.

Blood thinners (anticoagulants). Case-series data suggest that melatonin can alter clotting parameters in people on warfarin, producing changes in INR and prothrombin time 2Ref 2Tuft C, Matar E, Menczel Schrire Z, Grunstein RR, Yee BJ, Hoyos CM (2023).Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults.Peak melatonin concentrations in older adults up to 240% higher than younger adults; fall risk, blood pressure effects with nifedipine, interaction magnitude with fluvoxamine (2.8- to 12-fold increase), warfarin case evidence, and sedation risk. The mechanism is not fully established, but melatonin appears to have mild anticoagulant properties of its own. If you take warfarin, your clinician may want to check your INR sooner than usual after starting melatonin.

Blood pressure medications. Melatonin can modestly lower blood pressure, particularly during sleep. A meta-analysis of controlled-release melatonin formulations found a 3.57 mm Hg reduction in asleep systolic blood pressure 5Ref 5Lee EK, Poon P, Yu CP, Lee VWY, Chung VCH, Wong SYS (2022).Controlled-release oral melatonin supplementation for hypertension and nocturnal hypertension: A systematic review and meta-analysis.Controlled-release melatonin reduced asleep systolic blood pressure by 3.57 mm Hg in RCT meta-analysis; immediate-release did not show significant effect; evidence quality rated low to very low. In someone already taking antihypertensives, this could be additive — in most people this is not clinically important at typical supplement doses, but it is worth flagging if you are also on a calcium channel blocker such as nifedipine.

Sedatives, sleep aids, and opioids. Melatonin has a mild sedating effect. Layered on top of benzodiazepines, Z-drugs (zolpidem, eszopiclone), opioids, or antihistamines, melatonin can amplify drowsiness, impair coordination, and increase fall risk — particularly in older adults, in whom peak melatonin concentrations after a supplement dose can reach 240% higher than in adults under 45 2Ref 2Tuft C, Matar E, Menczel Schrire Z, Grunstein RR, Yee BJ, Hoyos CM (2023).Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults.Peak melatonin concentrations in older adults up to 240% higher than younger adults; fall risk, blood pressure effects with nifedipine, interaction magnitude with fluvoxamine (2.8- to 12-fold increase), warfarin case evidence, and sedation risk.

Diabetes medications (insulin and oral hypoglycemics). Research on melatonin and glucose is complex, and in some cases concerning. A 2022 randomized crossover trial in men with type 2 diabetes found that 10 mg of melatonin nightly for three months reduced insulin sensitivity by roughly 12% 6Ref 6Lauritzen ES, Kampmann U, Pedersen MGB, Christensen LL, Jessen N, Møller N, Støy J (2022).Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes — A randomized placebo-controlled crossover trial.10 mg melatonin nightly for 3 months reduced insulin sensitivity by ~12% (p=0.016) in a double-blind crossover trial of 17 men with type 2 diabetes; second-phase insulin secretion increased; authors recommend cautious use of high-dose melatonin in diabetic patients. Most over-the-counter doses are lower than that trial used, but the signal is clear enough that anyone on insulin or oral hypoglycemics should inform their diabetes care team before starting melatonin and monitor blood glucose more closely.

Immunosuppressants. Melatonin has immune-modulating properties. In people on cyclosporine or tacrolimus after transplant, or on similar agents for autoimmune disease, this interaction is best discussed with the prescribing specialist before starting any supplement.

Does the dose of melatonin change the interaction risk?

Yes, substantially. Over-the-counter melatonin in the United States is commonly sold in 5 mg and 10 mg doses, but research supports that physiological effects plateau well below those amounts. A 2013 meta-analysis of 19 randomized trials covering 1,683 participants found that melatonin reduced sleep onset latency by about 7 minutes and increased total sleep time by about 8 minutes overall, with effects on sleep onset latency more pronounced at higher doses 7Ref 7Ferracioli-Oda E, Qawasmi A, Bloch MH (2013).Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders.19 RCTs, 1,683 subjects; melatonin reduced sleep onset latency by ~7 minutes and increased total sleep time by ~8 minutes vs. placebo; effects modest but consistent and non-diminishing with continued use. But the dose required to match the body's natural nighttime melatonin output is in the range of 0.1 to 0.5 mg — far below what is typically sold.

For people taking interacting medications, starting at 0.5 mg — or even lower under medical guidance — reduces the chance that any pharmacokinetic or additive effect becomes clinically significant. High doses linger longer, particularly in older adults, increasing both the risk of next-morning grogginess and the magnitude of any interaction.

Timing also matters. Taking melatonin 30 to 60 minutes before the intended sleep time — rather than earlier in the evening — limits the window during which it overlaps with medications taken at other times of day.

Who should definitely check with a pharmacist or prescriber first?

A conversation before starting melatonin is worth the few minutes it takes if you are currently taking:

• Any antidepressant — and especially fluvoxamine
• Any blood thinner (warfarin, apixaban, rivaroxaban, dabigatran, or clopidogrel)
• Any blood pressure medication
• Insulin or any oral diabetes medication
• Any sedating prescription or OTC drug (benzodiazepines, Z-drugs, opioids, antihistamines)
• An immunosuppressant (cyclosporine, tacrolimus, mycophenolate, or similar)
• Any anti-seizure medication

For most people on these medications, melatonin is not automatically ruled out — but dosing, timing, and monitoring need to be considered with full knowledge of your medication list. A pharmacist is an underused resource here: they can review your full regimen and flag any interactions in a single appointment.

What does the evidence say about melatonin for sleep generally?

The strongest evidence for melatonin is in circadian rhythm disruption — jet lag, shift-work sleep disorder, and delayed sleep-wake phase disorder. A Cochrane review confirmed that melatonin taken close to the target bedtime is effective for jet lag 8Ref 8Herxheimer A, Petrie KJ (2002).Melatonin for the Prevention and Treatment of Jet Lag.Melatonin is effective for jet lag when taken at the target-bedtime destination; strongest evidence is for circadian rhythm disruption rather than general insomnia.

For general insomnia, the effect sizes are modest. The same 2013 meta-analysis that found a 7-minute reduction in sleep onset latency noted the authors themselves described the effects as small but consistent and non-diminishing with repeated use 7Ref 7Ferracioli-Oda E, Qawasmi A, Bloch MH (2013).Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders.19 RCTs, 1,683 subjects; melatonin reduced sleep onset latency by ~7 minutes and increased total sleep time by ~8 minutes vs. placebo; effects modest but consistent and non-diminishing with continued use.

The American Academy of Sleep Medicine's clinical guidelines designate cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia in adults — ahead of any medication or supplement [9, 10]. CBT-I has no drug interactions and produces durable improvements in sleep architecture. For someone already on multiple medications, the non-pharmacologic route is typically the most sensible place to start.

If an underlying condition is driving poor sleep — anxiety, depression, pain, restless legs, or sleep apnea — melatonin will not address the root cause. A clinician can assess and treat the source directly.